Can a new ultrasound technique spot hidden pancreatic cancers earlier?

NCT ID NCT06276764

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study evaluates a new diagnostic procedure called LINFU® to see if it can detect early pancreatic cancer and precancerous changes (dysplasia) in people with intraductal papillary mucinous neoplasm (IPMN), a condition that raises the risk of pancreatic cancer. Participants will undergo a 15-minute low-intensity ultrasound of the pancreas, receive a contrast agent and secretin, and have pancreatic juice collected for analysis. The goal is to compare LINFU®'s detection rate with standard imaging methods like EUS, MRI, and CT, and to see if it leads to earlier intervention and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LINFU® (low-intensity non-focused ultrasound with contrast agent and secretin)
What this could lead to
If successful, this could lead to a new screening method that catches pancreatic cancer earlier, potentially improving treatment options and outcomes.
What could go wrong
This is a registry study, not a randomized trial, so results may not prove effectiveness. The procedure involves contrast agents and secretin, which carry risks of allergic reactions or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IPMN, PANCREATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Manhattan Endoscopy Center

    New York, New York, 10007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.